Mario R. Ehlers

机构：University of California, San Francisco, Immune Tolerance Network

发表论文 100 篇 · 总被引 6369 次 · h-index 36

代表论文

• Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial (2013 · Diabetes · 被引 413)
• Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure (2019 · Pharmacological Reviews · 被引 354)
• Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs β-Cell Function (2012 · Diabetes · 被引 317)
• Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients (2015 · Journal of Clinical Investigation · 被引 294)
• Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes (2016 · Science Immunology · 被引 255)
• Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial (2013 · The Lancet Diabetes & Endocrinology · 被引 211)